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Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the standard 
therapy for non-small cell lung cancer (NSCLC) harboring EGFR mutations, but the resistance 
is inevitable. The drug-tolerant persister cancer cells are thought to be involved in the resistance. 
We recently reported that HER2 expression had a negative impact on time-to-treatment-failure 
in patients with EGFR mutant NSCLC. In this study, we hypothesized that HER2 might be a 
potential target for alternative combination therapy in NSCLC harboring EGFR mutations. In 
vitro study showed that the level of HER2 expression had no correlation with the sensitivity to 
EGFR-TKI, erlotinib but showed some correlation with HER2-inhibitor, ado-trastuzumab 
emtansine (T-DM1) in multiple EGFR-mutant lung cancer cell lines. In addition, HER2 
expression was increased in persister cancer cells in 11-18 cell line harboring EGFR L858R or 
HCC827 cell line harboring EGFR exon 19 deletion after the exposure to erlotinib in vitro and 
in vivo. The combination of erlotinib and T-DM1 showed a superior inhibitory effect on cell 
proliferation compared with those of the erlotinib or T-DM1 alone in either 11-18 or HCC827 
cells in vitro. The combination therapy also induced a significantly greater inhibitory effect on 
tumor growth in xenograft model in mice transplanted with either 11-18 or HCC827 cells 
compared with erlotinib alone or T-DM1 alone. No body weight loss was observed in these 
mice. These results suggested that the combination therapy with EGFR-TKI and T-DM1 might 
be a potentially promising strategy for treating lung cancer harboring EGFR mutations. 
